ClinicalTrials.gg

Program

Saccharomyces cerevisiae

Also written as “Saccharomyces Boulardii 250 MG”, “Probiotic : Saccharomyces boulardii” and “Saccharomyces boulardii”.

Its studies are mostly in Irritable Bowel Syndrome · Gastroenteritis · Diarrhea, led by Biocodex.

Furthest: phase 4, since May 16, 20183 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocodex31 open or runningphase 4since May 16, 2018Nov 2, 1999none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: phase 2 study in DiarrheaFirst studyNCT00002088 · 100 enrolled · United States
  2. May 16, 2018Phase 4 study in Acute GastroenteritisNCT03539913 · 317 enrolled · Argentina
  3. Aug 22, 2025Phase 3 study in Irritable Bowel SyndromeNCT07168434 · 406 planned · Portugal, Spain

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07168434Irritable Bowel Syndrome · Portugal, Spain3RecruitingOct 11, 2026406
NCT03539913Acute Gastroenteritis · Argentina4CompletedJun 9, 2018317
NCT00002088Diarrhea · United States2Completed100

How it is read

Names in the registry

  • “Saccharomyces Boulardii 250 MG”, 1 entry
  • “Probiotic : Saccharomyces boulardii”, 1 entry
  • “Saccharomyces boulardii”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.